Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
11.126
Zitationen
20
Autoren
2009
Jahr
Abstract
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)
Ähnliche Arbeiten
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 · 11.546 Zit.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
2020 · 9.709 Zit.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
2017 · 9.603 Zit.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 · 9.319 Zit.
Apixaban versus Warfarin in Patients with Atrial Fibrillation
2011 · 8.825 Zit.
Autoren
Institutionen
- McMaster University(CA)
- Population Health Research Institute(CA)
- Hamilton Health Sciences(CA)
- Lankenau Institute for Medical Research(US)
- Boehringer Ingelheim (United States)(US)
- Utrecht University(NL)
- St. John's National Academy of Health Sciences(IN)
- Fu Wai Hospital(CN)
- Estudios Clínicos Latinoamérica(AR)
- Carmel Medical Center(IL)
- Vivantes Klinikum(DE)
- University of Duisburg-Essen(DE)
- Sunnybrook Health Science Centre(CA)
- Health Sciences Centre(CA)